Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
Cancer
CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.
The VENTANA MET (SP44) RxDx Assay detects the MET, or c-Met, protein, which is overexpressed in about 25% of advanced NSQ-NSCLC patients with EGFR wild-type.
EMRELIS™ (telisotuzumab vedotin-tllv) used for previously treated adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression.
The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
Immunotherapies and other cancer treatments don’t work well on “cold” tumors, also known as immunological deserts, because they usually have few T cells.
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
According to the researchers, these recurring patterns suggest potential therapeutic targets meant to prevent or slow the progression of cancer.
Surgery to remove the tumor is the standard of care for individuals with stage III or IV clear cell renal cell carcinoma.
